LISATA THERAPEUTICS, INC.

Listed Company

LSTACIK 0000320017NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$170.0K

Net Income

$-16.59M

Total Assets

—

Equity

—

Shares Out

9.11M

Op. Cash Flow

$-15.95M

Business

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapies for solid tumors and other diseases. Its main product, certepetide (CEND-1), is an investigational iRGD peptide that activates the CendR pathway to increase tumor-specific uptake of co‑administered or tethered anti‑cancer drugs and to modulate the tumor microenvironment. Key activities include clinical development, collaborations and out‑licensing of the CendR Platform® and patent management. Lisata conducts global clinical trials in multiple solid tumor types and partners with academic groups, biotech and pharmaceutical collaborators for development and distribution.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	200,000	1	0	—	—
Research and development	8	11	13	13	18
General and administrative	10	12	13	—	—
Operating expenses	18	23	26	58	29
Operating loss	−18	−22	−26	−58	−29
Investment income, net	806,000	2	3	1	151,000
Other expense, net	−145,000	−257,000	−186,000	−155,000	−75,000
Total other income	661,000	2	3	897,000	76,000
Net loss before benefit from income taxes and noncontrolling interests	−18	−21	−23	−57	−29
Benefit from income taxes	−962,000	−798,000	−2	−2	−2
Net loss	−17	−20	−21	−54	−27
Less - net income (loss) attributable to noncontrolling interests	0	0	0	0	0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders	−17	−20	−21	−54	−27
Lisata Therapeutics, Inc. common stockholders - basic (in dollars per share)	−1.91	−2.4	−2.58	−10.47	−7.45
Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share)	−1.91	−2.4	−2.58	−10.47	−7.45
Basic (in shares)	9	8	8	5	4
Diluted (in shares)	9	8	8	5	4

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	16	16	23	32	25
Marketable securities	0	15	28	37	70
Accounts receivable	0	900,000	0	—	—
Prepaid and other current assets	2	2	3	3	1
Total current assets	18	35	54	72	96
Property and equipment, net	18,000	72,000	175,000	296,000	62,000
Acquired license-intangible, net	0	192,000	263,000	—	—
Other assets	23,000	160,000	332,000	528,000	764,000
Total assets	18	35	55	73	97
Accounts payable	1	1	2	3	2
Accrued liabilities	2	4	4	4	3
Total current liabilities	3	6	7	6	5
Other long-term liabilities	72,000	72,000	210,000	327,000	485,000
Total liabilities	3	6	7	7	5
Commitments and Contingencies (Note 14)	—	—	—	—	—
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,834,613 and 8,409,582 shares, at December 31, 2025 and December 31, 2024, respectively; and outstanding, 8,833,875 and 8,408,844 shares, at December 31, 2025 and December 31, 2024, respectively	9,000	8,000	8,000	8,000	4,000
Additional paid-in capital	580	578	577	575	546
Treasury stock, at cost; 738 shares at December 31, 2025 and December 31, 2024 respectively	−708,000	−708,000	−708,000	−708,000	—
Accumulated deficit	−565	−548	−528	−507	−453
Accumulated other comprehensive loss	−37,000	−81,000	−42,000	−29,000	−70,000
Total Lisata Therapeutics, Inc. stockholders' equity	15	30	48	67	92
Non-controlling interests	−254,000	−254,000	−254,000	−254,000	−254,000
Total equity	15	29	48	66	92
Total liabilities, non-controlling interests and stockholders' equity	18	35	55	73	97

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation expense	1	2	2	—	—
Depreciation and amortization	100,000	200,000	200,000	—	55,000
Loss from equity method investment	0	100,000	0	—	—
Impairment of non-financial asset	100,000	0	—	—	—
Amortization/accretion on marketable securities	−75,000	−455,000	−960,000	788,000	3
Allowance for credit losses	500,000	0	—	—	—
Accounts receivable	401,000	−900,000	0	—	—
Prepaid and other current assets	742,000	852,000	−824,000	−845,000	−453,000
Other assets	140,000	170,000	274,000	237,000	−150,000
Accounts payable, accrued liabilities and other liabilities	−3	−995,000	88,000	−223,000	1
Net cash used in operating activities	−16	−19	−20	−21	−22
Purchase of marketable securities	−9	−56	−98	−90	−180
Sales of marketable securities	24	69	109	122	125
Investment in Impilo Therapeutics	0	−130,000	0	—	—
Purchases of property and equipment	−28,000	0	0	−285,000	−60,000
Net cash provided by investing activities	15	13	10	29	−55
Proceeds from exercise of options	8,000	0	155,000	0	24,000
Tax withholding payments on net share settlement equity awards	−253,000	−274,000	−91,000	−267,000	−248,000
Net proceeds from issuance of common stock	844,000	68,000	321,000	43,000	86
Net cash provided by (used in) financing activities	599,000	−206,000	385,000	−224,000	85
Effect of exchange rate changes on cash	11,000	−55,000	−16,000	−10,000	0
Net decrease in cash and cash equivalents	−253,000	−6	−10	8	8

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro